KRAS and cancer: The oncogenic KRAS G13D mutation in MDA-MB-231 may explain the suppression of the IFN-I response and the activation of NF-κB signaling and IL-6 expression, which have been already reported for KRAS-mutated cancers [23, 24, 47].